- Home
- ATLO vs IPHA Comparison
ATLO vs IPHA Comparison
Compare ATLO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLO
- IPHA
- Stock Information
- Founded
- ATLO 1903
- IPHA 1999
- Country
- ATLO United States
- IPHA France
- Employees
- ATLO N/A
- IPHA N/A
- Industry
- ATLO Major Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ATLO Finance
- IPHA Health Care
- Exchange
- ATLO Nasdaq
- IPHA Nasdaq
- Market Cap
- ATLO 180.3M
- IPHA 160.1M
- IPO Year
- ATLO N/A
- IPHA 2019
- Fundamental
- Price
- ATLO $21.24
- IPHA $1.79
- Analyst Decision
- ATLO
- IPHA Strong Buy
- Analyst Count
- ATLO 0
- IPHA 3
- Target Price
- ATLO N/A
- IPHA $5.00
- AVG Volume (30 Days)
- ATLO 22.1K
- IPHA 25.8K
- Earning Date
- ATLO 10-17-2025
- IPHA 09-17-2025
- Dividend Yield
- ATLO 3.83%
- IPHA N/A
- EPS Growth
- ATLO 82.22
- IPHA N/A
- EPS
- ATLO 1.79
- IPHA N/A
- Revenue
- ATLO $60,568,000.00
- IPHA $14,839,695.00
- Revenue This Year
- ATLO N/A
- IPHA $50.89
- Revenue Next Year
- ATLO N/A
- IPHA N/A
- P/E Ratio
- ATLO $11.72
- IPHA N/A
- Revenue Growth
- ATLO 18.60
- IPHA N/A
- 52 Week Low
- ATLO $15.75
- IPHA $1.29
- 52 Week High
- ATLO $21.48
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ATLO 61.50
- IPHA 36.92
- Support Level
- ATLO $20.65
- IPHA $1.95
- Resistance Level
- ATLO $21.14
- IPHA $2.40
- Average True Range (ATR)
- ATLO 0.41
- IPHA 0.11
- MACD
- ATLO 0.05
- IPHA -0.04
- Stochastic Oscillator
- ATLO 88.42
- IPHA 0.00
About ATLO Ames National Corporation
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.